Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma

Chinese Journal of Cancer

Volumn 32, Issue 1, 2013, Pages 3-11

  Li, Ji Sheng ^a   Ying, Jian Ming ^b   Wang, Xiu Wen ^a   Wang, Zhao Hui ^c,d   Tao, Qian ^c,d   Li, Li Li ^c,d  

^a SHANDONG UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

Author keywords

CpG island; Esophageal squamous cell carcinoma; Promoter methylation; Tumor marker; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; EPIGALLOCATECHIN GALLATE; N PHTHALOYLTRYPTOPHAN; TUMOR MARKER; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE CONTROL GENE; CELL CYCLE REGULATION; CPG ISLAND; DNA METHYLATION; DNA REPAIR; DNA REPAIR GENE; DRUG MECHANISM; DRUG TARGETING; EARLY DIAGNOSIS; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE; GENE MUTATION; GENE SILENCING; GENETIC DISORDER; GENETIC REGULATION; GROWTH FACTOR RESPONSE RELATED GENE; HUMAN; METASTASIS ANTAGONIZING GENE; METASTASIS POTENTIAL; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRELEUKEMIA; PROAPOPTOTIC GENE; PROMOTER REGION; REGULATOR GENE; REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84872172807     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10381     Document Type: Review

References (117)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005,55:74-108.
2. Lambert R, Hainaut P. Esophageal cancer: cases and causes (part I). Endoscopy, 2007,39:550-555.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med, 2003,349: 2241-2252.
4. Umar SB, Fleischer DE. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol, 2008,5:517-526.
5. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol, 2007,17:2-9.
6. McCabe ML, Dlamini Z. The molecular mechanisms of oesophageal cancer. Int Immunopharmacol, 2005,5:1113-1130.
7. Chen X, Hu H, Guan X, et al. CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer, 2012,130:1607-1613.
8. Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-lik e growth factor 1 receptor. Gut, 2011,61:33-42.
9. Kamb A. Cyclin-dependent kinase inhibitors and human cancer. Curr Top Microbiol Immunol, 1998,227:139-148.
10. Tokugawa T, Sugihara H, Tani T, et al. Modes of silencing of p16 in development of esophageal squamous cell carcinoma. Cancer Res, 2002,62: 4938-4944.
11. Xing EP, Nie Y, Song Y, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esopha-geal squamous cell carcinoma. Clin Cancer Res, 1999,5:2704-2713.
12. Xing EP, Nie Y, Wang LD, et al. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis, 1999,20:77-84.
13. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 2000,25:315-319.
14. Kuroki T, Trapasso F, Yendamuri S, et al. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res, 2003,9:1441-1445.
15. Wong ML, Tao Q, Fu L, et al. Aberrant promoter hyper-methylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squa-mous cell carcinoma. Int J Oncol, 2006,28:767-773.
16. Shibata Y, Haruki N, Kuwabara Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis, 2002,23:1695-1699.
17. Bialik S, Kimchi A. DAP-k inase as a target for drug design in cancer and diseases associated with accelerated cell death. Semin Cancer Biol, 2004,14:283-294.
18. Gozuacik D, Kimchi A. DAPk protein family and cancer. Autophagy, 2006,2:74-79.
19. Ishii T, Murakami J, Notohara K, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut, 2007,56:13-19.
20. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell, 2002,109:113-124.
21. Long C, Yin B, Lu Q, et al. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest, 2007,25:685-690.
22. Tonomoto Y, Tachibana M, Dhar DK, et al. Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis. Oncology, 2007,73:346-356.
23. Yu J, Tao Q, Cheung KF, et al. Epigenetic identification of ubiquitin carboxyl-te rminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology, 2008,48: 508-518.
24. Mandelker DL, Yamashita K, Tokumaru Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res, 2005,65: 4963-4968.
25. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci, 1999,24:73-76.
26. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol, 2002,12:373-379.
27. Si HX, Tsao SW, Lam KY, et al. E-c adherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett, 2001,173:71-78.
28. Takeno S, Noguchi T, Fumoto S, et al. E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. Am J Clin Pathol, 2004, 122:78-84.
29. Lee EJ, Lee BB, Han J, et al. CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int J Cancer, 2008,123:2073-2079.
30. Li L, Ying J, Li H, et al. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene, 2011. [Epub ahead of print]
31. Jin Z, Cheng Y, Olaru A, et al. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer, 2008,123:2331-2336.
32. Roth MJ, Abnet CC, Hu N, et al. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol Rep, 2006,15:1591-1597.
33. Sung CO, Han SY, Kim SH. Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol, 2011,18: 273-281.
34. Park HL, Kim MS, Yamashita K, et al. DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer, 2008,122:2498-2502.
35. Nakagawa T, Pimkhaokham A, Suzuki E, et al. Genetic or epigenetic silencing of low density lipoprotein receptor-re lated protein 1B expression in oral squamous cell carcinoma. Cancer Sci, 2006,97:1070-1074.
36. Ying J, Li H, Seng TJ, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene, 2006,25: 1070-1080.
37. Haruki S, Imoto I, Kozaki K, et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esopha-geal squamous cell carcinoma. Carcinogenesis, 2010,31:1027-1036.
38. Ito T, Shimada Y, Hashimoto Y, et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res, 2003,63:6320-6326.
39. Margison GP, Povey AC, Kaina B, et al. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcino-genesis, 2003,24:625-635.
40. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res, 2006,12:328-331.
41. Fang MZ, Jin Z, Wang Y, et al. Promoter hypermethylation and inactivation of O(6)-m ethylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol, 2005,26:615-622.
42. Zhang L, Lu W, Miao X, et al. Inactivation of DNA repair gene O6-m ethylguanine-D NA methyltransferase by promoter hyper-methylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis, 2003,24:1039-1044.
43. Wang J, Sasco AJ, Fu C, et al. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev, 2008,17:118-125.
44. Lu C, Xie H, Wang F, et al. Diet folate, DNA methylation and genetic polymorphisms of MTHFR C677T in association with the prognosis of esophageal squamous cell carcinoma. BMC Cancer, 2011,11:91.
45. Bignami M, Casorelli I, Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer, 2003,39:2142-2149.
46. Chung DC, Rustgi AK. DNA mismatch repair and cancer. Gastroenterology, 1995,109:1685-1699.
47. Tzao C, Hsu HS, Sun GH, et al. Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg, 2005,130:1371.
48. Vasavi M, Kiran V, Ravishankar B, et al. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. Cancer Biomark, 2010,7:1-10.
49. Guo M, Ren J, House MG, et al. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res, 2006,12:4515-4522.
50. Zhang GY, Ma CX, Liu QL, et al. Detection of methylation of hMSH2 gene promoter region of esophageal cancer. Zhonghua Zhong Liu Za Zhi, 2005, 27:541-543. [in Chinese]
51. Pekarsky Y, Zanesi N, Palamarchuk A, et al. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol, 2002,3:748-754.
52. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol, 1999,17:1618-1624.
53. Tanaka H, Shimada Y, Harada H, et al. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res, 1998,58:3429-3434.
54. Mori M, Mimori K, Shiraishi T, et al. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res, 2000,60:1177-1182.
55. Lee EJ, Lee BB, Kim JW, et al. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer, 2006,42:972-980.
56. Soma T, Kaganoi J, Kawabe A, et al. Nicotine induces the fragile histidine triad methylation in human esophageal squamous epithelial cells. Int J Cancer, 2006,119:1023-1027.
57. Xu XC. Tumor-s uppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett, 2007,253:14-24.
58. Qiu H, Zhang W, El-Naggar AK, et al. Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis. Am J Pathol, 1999,155:1519-1523.
59. Qiu H, Lotan R, Lippman SM, et al. Lack of correlation between expression of retinoic acid receptor-beta and loss of heterozygosity on chromosome band 3p24 in esophageal cancer. Genes Chromosomes Cancer, 2000,28:196-202.
60. Li J, Liu Z, Wang Y, et al. Allelic imbalance of chromosome 1q in esophageal squamous cell carcinomas from China: a novel region of allelic loss and significant association with differentiation. Cancer Lett, 2005,220:221-230.
61. Wang Y, Fang MZ, Liao J, et al. Hypermethylation-associated inactivation of retinoic acid receptor beta in human esophageal squamous cell carcinoma. Clin Cancer Res, 2003,9:5257-5263.
62. Cottrell SE, Laird PW. Sensitive detection of DNA methylation. Ann N Y Acad Sci, 2003,983:120-130.
63. Cottrell SE. Molecular diagnostic applications of DNA methylation technology. Clin Biochem, 2004,37:595-604.
64. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol, 2009,625:131-142.
65. Jin Z, Olaru A, Yang J, et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res, 2007,13: 6293-6300.
66. Adams L, Roth MJ, Abnet CC, et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. Cancer Prev Res (Phila), 2008,1: 357-361.
67. Li B, Wang B, Niu LJ, et al. Hypermethylation of multiple tumor-re lated genes associated with DNMT3b up-re gulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics, 2011,6:307-316.
68. Ling ZQ, Li P, Ge MH, et al. Hypermethylation-m odulated down-re gulation of CDH1 expression contributes to the progression of esophageal cancer. Int J Mol Med, 2011,27: 625-635.
69. Zare M, Jazii FR, Alivand MR, et al. Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer, 2009,9:24.
70. Kim MS, Yamashita K, Baek JH, et al. N-m ethyl-D -aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-s uppressive activity in human esophageal cancer. Cancer Res, 2006,66:3409-3418.
71. Ninomiya I, Kawakami K, Fushida S, et al. Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep, 2008,20:1489-1495.
72. Kong KL, Kwong DL, Fu L, et al. Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. Cancer Res, 2010,70:8832-8841.
73. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-a za-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res, 1998,58:95-101.
74. Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs, 2002,3:627-633.
75. Kagan J, Srivastava S, Barker PE, et al. Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI's EDRN and NIST workshop on standards, methods, assays, reagents and tools. Cancer Res, 2007,67:4545-4549.
76. Beck S, Rakyan VK. The methylome: approaches for global DNA methylation profiling. Trends Genet, 2008,24:231-237.
77. Cheng Y, Geng H, Cheng SH, et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res, 2010,70:6516-6526.
78. Anupam K, Tusharkant C, Gupta SD, et al. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol, 2006,12:6041-6045.
79. Tanaka K, Imoto I, Inoue J, et al. Frequent methylation-associated silencing of a candidate tumor-s uppressor, CRABP1, in esophageal squamous-cell carcinoma. Oncogene, 2007,26:6456-6468.
80. Mizuiri H, Yoshida K, Toge T, et al. DNA methylation of genes linked to retinoid signaling in squamous cell carcinoma of the esophagus: DNA methylation of CRBP1 and TIG1 is associated with tumor stage. Cancer Sci, 2005,96: 571-577.
81. Hussain S, Singh N, Salam I, et al. Methylation-m ediated gene silencing of suppressor of cytokine signaling-1 (SOCS-1) gene in esophageal squamous cell carcinoma patients of Kashmir valley. J Recept Signal Transduct Res, 2011,31:147-156.
82. Meng Y, Wang QG, Wang JX, et al. Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma. Dig Dis Sci, 2011,56:3195-3203.
83. Zhang W, Glockner SC, Guo M, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res, 2008,68:2764-2772.
84. Chan SL, Cui Y, van Hasselt A, et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyn-geal and esophageal carcinomas. Lab Invest, 2007,87:644-650.
85. Li J, Ying J, Fan Y, et al. WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther, 2010,10:617-624.
86. Lo PH, Leung AC, Kwok CY, et al. Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene, 2007,26:148-157.
87. Jin H, Wang X, Ying J, et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene, 2007,26:7490-7498.
88. Yi Lo PH, Chung Leung AC, Xiong W, et al. Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-re gulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett, 2006,234:184-192.
89. Guo M, House MG, Suzuki H, et al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer, 2007,121:1219-1226.
90. Wang Y, Li J, Cui Y, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res, 2009,69:5194-5201.
91. Shao L, Cui Y, Li H, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res, 2007,13:5756-5762.
92. Seng TJ, Low JS, Li H, et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene, 2007,26:934-944.
93. Daigo Y, Nishiwaki T, Kawasoe T, et al. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res, 1999,59: 1966-1972.
94. Yue CM, Deng DJ, Bi MX, et al. Expression of ECRG4, a novel esophageal cancer-re lated gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol, 2003,9: 1174-1178.
95. Zhao BJ, Sun DG, Zhang M, et al. Identification of aberrant promoter methylation of EDNRB gene in esophageal squamous cell carcinoma. Dis Esophagus, 2009,22:55-61.
96. Fumoto S, Hiyama K, Tanimoto K, et al. EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. Cancer Lett, 2009,274:25-32.
97. Wong VC, Chan PL, Bernabeu C, et al. Identification of an invasion and tumor-s uppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer, 2008, 123: 2816-2823.
98. Guo M, House MG, Akiyama Y, et al. Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer, 2006,119:2078-2083.
99. He Y, Wang Y, Li P, et al. Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma. Dig Dis Sci, 2011,56:681-688.
100. Liu R, Yin L, Pu Y, et al. Functional alterations in the glutathione S-transferase family associated with enhanced occurrence of esophageal carcinoma in China. J Toxicol Environ Health A, 2010,73:471-482.
101. Guo M, Ren J, Brock MV, et al. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics, 2008,3:336-341.
102. Qifeng S, Bo C, Xingtao J, et al. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics. J Thorac Cardiovasc Surg, 2011,141: 808-814.
103. Hibi K, Nakayama H, Kanyama Y, et al. Methylation pattern of HLTF gene in digestive tract cancers. Int J Cancer, 2003,104: 433-436.
104. Yamashita K, Kim MS, Park HL, et al. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma. Mol Cancer Res, 2008,6:31-41.
105. Chang X, Yamashita K, Sidransky D, et al. Promoter methylation of heat shock protein B2 in human esophageal squamous cell carcinoma. Int J Oncol, 2011,38:1129-1135.
106. Lee KY, Geng H, Ng KM, et al. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene, 2008,27:5267-5276.
107. Smith E, Drew PA, Tian ZQ, et al. Metallothionien 3 expression is frequently down-re gulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer, 2005,4:42.
108. Kim MS, Chang X, LeBron C, et al. Neurofilament heavy polypeptide regulates the Akt-beta-catenin pathway in human esophageal squamous cell carcinoma. PLoS One, 2010,5: e9003.
109. Jin Z, Mori Y, Yang J, et al. Hypermethylation of the nel-lik e 1 gene is a common and early event and is associated with poor prognosis in early-s tage esophageal adenocarcinoma. Oncogene, 2007,26:6332-6340.
110. Zhang C, Li K, Wei L, et al. p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J Clin Pathol, 2007,60:1249-1253.
111. Zhu C, Qin YR, Xie D, et al. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene, 2009,28:2821-2828.
112. Fu L, Qin YR, Xie D, et al. Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res, 2007,67:10720-10726.
113. Jin Z, Mori Y, Hamilton JP, et al. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer, 2008,112:43-49.
114. Ko JM, Chan PL, Yau WL, et al. Monochromosome transfer and microarray analysis identify a critical tumor-s uppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. Mol Cancer Res, 2008,6:592-603.
115. Zhao BJ, Tan SN, Cui Y, et al. Aberrant promoter methylation of the TPEF gene in esophageal squamous cell carcinoma. Dis Esophagus, 2008,21:582-588.
116. Yamashita K, Mimori K, Inoue H, et al. A tumor-s uppressive role for trypsin in human cancer progression. Cancer Res, 2003,63:6575-6578.
117. Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res, 2003,63: 3724-3728.